Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma. 2018

Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

BACKGROUND Coagulation and nutrition play important roles in cancer progression. The aim of the present study is to evaluate the prognostic value of the preoperative fibrinogen/albumin ratio (FAR) in surgical patients with soft tissue sarcoma (STS) and to compare this value with other inflammatory biomarkers. In addition, we investigated the relationship between FAR and the clinicopathological characteristics of STS patients. METHODS We included 310 STS patients in this retrospective study. Kaplan-Meier curves, univariate and multivariate Cox proportional models were used in the prognostic analyses. RESULTS According to the receiver operating characteristic (ROC) analysis, the optimal FAR cut-off value was 0.0726. The FAR exhibited a greater area under the curve (AUC) value (0.680) than did the NLR and PLR. An elevated FAR (≥0.0726) was significantly associated with an old age, large tumor size, deep tumor location, high tumor grade, and advanced American Joint Committee on Cancer (AJCC) stage. Patients with an increased FAR had a shorter median survival time and a lower 5-year overall survival (OS) rate than did those with a low FAR (61.0 vs115.8 months, P < 0.001; 56.7% vs 82.4%, P < 0.001, respectively). Multivariate analysis indicated FAR (Hazard ratio (HR) 1.907, 95% confidence interval (CI) 1.161-3.132, P < 0.001) to be an independent prognostic factor for OS, as were tumor depth, grade and PLR. CONCLUSIONS Preoperative FAR is associated with tumor progression and can be considered an independent factor for OS of resected STS patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
April 2021, Medicine,
Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
January 2021, Journal of Cancer,
Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
December 2024, The Libyan journal of medicine,
Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
April 2015, Oncotarget,
Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
December 2022, International immunopharmacology,
Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
November 2023, BMC cardiovascular disorders,
Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
September 2018, Medicine,
Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
April 2016, Oncology (Williston Park, N.Y.),
Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
March 2023, Medical science monitor : international medical journal of experimental and clinical research,
Yao Liang, and Wei Wang, and Yi Que, and Yuanxiang Guan, and Wei Xiao, and Cheng Fang, and Xing Zhang, and Zhiwei Zhou
November 2022, Journal of personalized medicine,
Copied contents to your clipboard!